Citation: Tsuyoshi Inoshita, Yuzuru Imai. Regulation of vesicular trafficking by Parkinson's disease-associated genes[J]. AIMS Molecular Science, 2015, 2(4): 461-475. doi: 10.3934/molsci.2015.4.461
| [1] | Ruijin Hong, Jialin Ji, Chunxian Tao, Daohua Zhang, Dawei Zhang . Fabrication of Au/graphene oxide/Ag sandwich structure thin film and its tunable energetics and tailorable optical properties. AIMS Materials Science, 2017, 4(1): 223-230. doi: 10.3934/matersci.2017.1.223 |
| [2] | Claas Hüter, Shuo Fu, Martin Finsterbusch, Egbert Figgemeier, Luke Wells, Robert Spatschek . Electrode–electrolyte interface stability in solid state electrolyte systems: influence of coating thickness under varying residual stresses. AIMS Materials Science, 2017, 4(4): 867-877. doi: 10.3934/matersci.2017.4.867 |
| [3] | Dong Geun Lee, Hwan Chul Yoo, Eun-Ki Hong, Won-Ju Cho, Jong Tae Park . Device performances and instabilities of the engineered active layer with different film thickness and composition ratios in amorphous InGaZnO thin film transistors. AIMS Materials Science, 2020, 7(5): 596-607. doi: 10.3934/matersci.2020.5.596 |
| [4] | Sree Sourav Das, Zach Fox, Md Dalim Mia, Brian C Samuels, Rony Saha, Ravi Droopad . Demonstration of ferroelectricity in PLD grown HfO2-ZrO2 nanolaminates. AIMS Materials Science, 2023, 10(2): 342-355. doi: 10.3934/matersci.2023018 |
| [5] | Ravipati Praveena, Gottapu. Varaprasada Rao, Karna Balasubrahmanyam, M. Ghanashyam Krishna, Vinjanampati Madhurima . Optical and water repellant properties of Ag/SnO2 bilayer thin films. AIMS Materials Science, 2016, 3(1): 231-244. doi: 10.3934/matersci.2016.1.231 |
| [6] | Wiebke Langgemach, Andreas Baumann, Manuela Ehrhardt, Thomas Preußner, Edda Rädlein . The strength of uncoated and coated ultra-thin flexible glass under cyclic load. AIMS Materials Science, 2024, 11(2): 343-368. doi: 10.3934/matersci.2024019 |
| [7] | Hyeck Go, Eun-Mi Han, Moon Hee Kang, Yong Hyun Kim, Changhun Yun . The coated porous polyimide layers for optical scattering films. AIMS Materials Science, 2018, 5(6): 1102-1111. doi: 10.3934/matersci.2018.6.1102 |
| [8] | Avinash Kumar Both, Chin Li Cheung . Lateral growth of xenon hydrate films on mica. AIMS Materials Science, 2021, 8(5): 776-791. doi: 10.3934/matersci.2021047 |
| [9] | G. A. El-Awadi . Review of effective techniques for surface engineering material modification for a variety of applications. AIMS Materials Science, 2023, 10(4): 652-692. doi: 10.3934/matersci.2023037 |
| [10] | Takuto Eguchi, Shinya Kato, Naoki Kishi, Tetsuo Soga . Effect of thickness on photovoltaic properties of amorphous carbon/fullerene junction. AIMS Materials Science, 2022, 9(3): 446-454. doi: 10.3934/matersci.2022026 |
The development of layer-by-layer (LbL) films and microcapsules has been a key subject in polymer science and technology [1,2,3,4,5]. LbL films are prepared by the successive deposition of polymeric materials on the surface of solid substrates, such as metals, glass, and polymers, through attractive forces, including electrostatic interactions, hydrogen bonding, and biological affinity. Thus, a variety of synthetic and biological materials can be used as components of LbL assemblies. LbL assemblies are characterized by well-defined stratified structures containing the polymeric materials.
LbL films can be prepared from a cationic and an anionic polymer through the electrostatic affinity between them. The adsorption of charged polymers on an oppositely charged surface produces a new surface with the opposite charge, resulting from overcompensation of the surface charge. The over-compensated surface enables the deposition of the next layer of an oppositely charged polymer. In a typical procedure, the solid substrate is alternately immersed in aqueous solutions of the polymers, followed by rinsing to remove nonspecifically or weakly adsorbed polymers (Figure 1a). The thickness of the film can be regulated simply by changing the number of deposited layers, because film thickness increases with the number of depositions. Biopolymers, such as proteins [6,7], polysaccharides [8,9], and DNA [10,11], can also be used as building blocks for constructing LbL films, because these biopolymers contain net electric charges.
Figure 1. Preparation of LbL films (a) and microcapsules (b).Hydrogen bonding can also be used as a driving force for constructing LbL films. Poly(acrylic acid) (PAA) and poly(methacrylic acid) (PMA) are often used as hydrogen bonding donor polymers in combination with hydrogen bonding acceptors, such as poly(ethylene glycol) [12,13]. An interesting feature of hydrogen-bonded LbL films is their pH-dependent stability. LbL films consisting of PAA and PMA are stable in acidic solutions, whereas these films decompose in neutral and basic media because the hydrogen bonds are broken via deprotonation of the carboxylic acid residues. Proteins can also be used as components of LbL films, in which film formation relies on biological affinity. For example, concanavalin A and avidin, which specifically bind sugars and biotin, respectively, are used to construct LbL films [14,15,16].
Hollow microcapsules can be constructed by LbL deposition of polymers on the surfaces of colloidal particles, such as CaCO3 microspheres, followed by dissolution of the core (Figure 1b). These polymer microcapsules are stable over a wide pH range. Therefore, LbL microcapsules are being widely studied as drug carriers [17,18,19]. An advantage of LbL microcapsules is that the structure of their shell membrane can be tailored at the molecular level by using suitable materials. LbL films and microcapsules have been used in applications such as separation and purification membranes [20,21], optical and electrochemical sensors [22,23], drug delivery systems [24,25], and self-healing gels [26,27].
Recently, much attention has been devoted to constructing cyclodextrin (CD)-containing LbL assemblies and their use in biosensing and drug delivery. CDs are naturally occurring cyclic oligosaccharides composed of D-glucose units linked with α-1, 4-glucosidic bonds. α-CD, β-CD, and γ-CD, which consist of six, seven, and eight D-glucose units, respectively, have been widely used and are currently commercially available (Figure 2). CDs bind low-molecular-weight compounds in their hydrophobic cavity to form host–guest inclusion complexes [28,29,30] and are non-toxic; thus, CDs are used in foods, cosmetics, and drugs as solubilizers or stabilizers [31,32,33]. Furthermore, CDs have been used as molecular recognition elements in constructing devices for biosensing and drug delivery [34,35,36,37], in which CDs are immobilized in polymer matrices such as thin films and gels. Consequently, the preparation of CD-containing polymer matrices is a key step in the development of high-performance CD-based devices.
Figure 2. Chemical structures of α-CD (n = 6), β-CD (n = 7) and γ-CD (n = 8).This paper gives an overview of CD-containing thin films and microcapsules prepared by LbL deposition. The strategies used in the synthesis of these assemblies and their biomedical applications are discussed.
There are two types of synthetic strategy for CD-containing LbL assemblies based on the type of driving force used for assembly. The first strategy is to use charged CDs, and the LbL assemblies are prepared through electrostatic affinity. In this protocol, charged CDs, such as sulfonated CDs, are used as film components in combination with positively charged polymers. Sulfonated CDs are currently commercially available. The second strategy for constructing CD-containing LbL assemblies relies on the host–guest complexation between CD and guest molecules as a driving force for assembly. In this route, CD polymers and guest molecule-appended polymers are built into LbL layers by forming host–guest complexes. CD-capped nanoparticles are also useful as components of LbL assemblies in this protocol.
The first example of CD-containing LbL films was reported by Swanson and coworkers [38]. They used α-CD substituted with sulfonate groups (s-α-CD, Figure 3) to prepare LbL films by alternate deposition of the s-α-CD with poly(diallyldimethylammonium chloride) (PDDA). The s-α-CD/PDDA films were tested as a sensitive layer in surface acoustic wave sensors for measuring volatile organic compounds (VOCs). However, full experimental details for the preparation of the s-α-CD/PDDA films were not provided.
Figure 3. Chemical structures of s-α-CD (n = 6), s-β-CD (n = 7), methyl orange, and Az-PAH.Later, our group prepared LbL films containing s-α-CD and s-β-CD (Figure 3), which contain nominally 12 and 14 sulfonate groups in a single molecule, by alternate deposition of the sulfonated CDs with poly(allylamine hydrochloride) (PAH) [39,40]. A quartz crystal microbalance (QCM) study showed that the sulfonated CDs and PAH form LbL films through electrostatic affinity. The loading of CDs in the films depended strongly on the ionic strength of the bathing solutions from which the CDs and PAH were deposited. Thus, LbL films prepared using CDs and PAH solutions with higher ionic strength allowed thicker films that contained higher amounts of CDs. The thickness of the (s-α-CD/PAH)10 and (s-β-CD/PAH)10 films prepared from water solution without salts was typically 22 and 23 nm, respectively, while the film thickness was more than 10-times higher when the films were prepared from buffer solutions containing 140 mM NaCl. Interestingly, methyl orange (Figure 3) formed inclusion complexes with s-α-CD in the s-α-CD/PAH film, whereas no inclusion complex formed in the s-β-CD/PAH film. Instead, methyl orange formed aggregations in the s-β-CD/PAH film as a result of electrostatic binding to the positive sites in the film. These results demonstrated that the binding ability of CDs can be preserved, even in the LbL films. LbL films consisting of azobenzene-bearing PAH (Az-PAH, Figure 3) and sulfonated CDs were also prepared through electrostatic affinity [41]. The UV-visible absorption spectrum of the s-α-CD/Az-PAH film contained an absorption maximum at 335 nm originating from the π–π* transition of the azobenzene residues, whereas the absorption maximum was at 326 nm for the s-b-CD/Az-PAH film. The results were explained by the formation of an inclusion complex between azobenzene residues and s-α-CD in the film.
Carboxymethylated β-CD (CM-β-CD) has also been used for constructing LbL films [42]. Negatively charged CM-β-CD and positive polymer diazoresin were alternately deposited to form LbL films on a quartz slide, followed by photochemical crosslinking of CM-β-CD and diazoresin in the film. This process provided covalently crosslinked LbL films containing CD moieties. The CM-β-CD-containing LbL films showed strong binding to the cationic dye methylene blue through host–guest complexation.
Recently, Kim and coworkers synthesized cationic and anionic β-CD oligomers and tried to use them for constructing LbL films [43]. However, film construction failed, probably due to the limited numbers of ionic sites in the β-CD oligomers. On the other hand, polyrotaxanes (PRXs) consisting of cationic and anionic α-CDs were synthesized to construct LbL microcapsules [44]. The alternate deposition of PRXs comprising cationic and anionic α-CDs on the surface of silica (SiO2) microspheres followed by dissolution of the SiO2 core provided hollow microcapsules. The microcapsules disintegrated in response to glutathione (GSH). This result was ascribed to GSH-induced decomposition of the PRXs, which arose from the cleavage of disulfide bonds in the rotaxanes by GSH. The PRXs-based microcapsules may be useful in the development of drug delivery systems because the decomposition products of the microcapsules (i.e., CDs and polyethylene glycol) are biocompatible.
Another route for constructing CD-containing LbL assembly relies on the formation of host–guest inclusion complexes as the driving force. Suzuki and coworkers reported the first example of LbL films prepared through host–guest complexation by using ferrocene-bearing PAH (Fc-PAH) and a disulfide-linked β-CD dimer (Figure 4) [45]. It was anticipated that Fc-PAH chains could be crosslinked with the β-CD dimer to form LbL films. In fact, the QCM study showed that the alternate deposition of Fc-PAH and the β-CD dimer provided a (Fc-PAH/β-CD dimer)3 film. A critical role of the host–guest complexation between the ferrocene moiety of Fc-PAH and β-CD dimer in the film formation was confirmed by the fact that the LbL film did not form when the deposition was carried out with unmodified PAH instead of Fc-PAH or with monomeric β-CD instead of the dimer. Furthermore, no LbL film was obtained when the deposition was performed in the presence of competitive binders to the β-CD dimer, such as ferrocenecarboxylic acid and cyclohexanol.
Figure 4. Chemical structures of Fc-PAH and β-CD dimer.Polymeric CDs can also be used to construct LbL films. For instance, chitosan derivatives modified with β-CD (CD-Chi) or adamantane (Ad-Chi) were used as host and guest polymers, respectively [46]. The alternate deposition of these chitosan derivatives provided multilayer films by forming host–guest complexes, overcoming electrostatic repulsion between positive charges in the chitosan derivatives. The binding force between CD-Chi and Ad-Chi was evaluated by direct force measurements with an atomic force microscope [47]. The thicker LbL films comprising charged polymers were rather unstable due to the electrostatic repulsion between the polymers. To stabilize LbL films, poly(acrylamide) (PAAm) derivatives modified with ferrocene and β-CD, which bear no electric charge, were used as film components [48]. The PAAm-based films were deposited up to the 30th layer by avoiding electrostatic repulsion in the film. LbL films comprising well-ordered chromophores have been prepared by using perylene diimide derivatives containing β-CD (CD-PDI) or Ad (Ad-PDI) [49]. CD-PDI and Ad-PDI chromophores were linked with each other through host–guest interactions to form LbL layers.
An advantage of LbL deposition is the wide choice of film components, including carbon nanomaterials [50,51] and metal nanoparticles [52,53]. CD-capped Au nanoparticles were used to prepare an LbL assembly through host–guest complexation [54,55] (Figure 5). LbL deposition of the CD-capped Au nanoparticles and Ad-modified poly(amidoamine) (PAMAM) dendrimer gave well-defined multilayer films. CD-capped poly(styrene) nanoparticles were also useful for constructing LbL microcapsules by combining with Fc-modified poly(ethyleneimine) [56]. These microcapsules were decomposed by a competitive binder, such as Ad, suggesting that they could be used as a microcontainer for controlled release.
Figure 5. LbL deposition of the Ad-modified PAMAM dendrimer and CD-capped Au nanoparticles. Reprinted with permission from Huskens et al. [54].Polymer films have widely been studied as surface coatings sensitive to ions and molecules for constructing optical, gravimetric, and electrochemical devices [57,58,59,60]. Polymer films can be prepared by various techniques, including physical adsorption, crosslinking, dip-coating, drop-casting, and photo-and electro-polymerization. The conventional protocols for constructing polymer films do not have a mechanism to regulate the fine structure of the polymer films and their thickness at the molecular level. In contrast, LbL deposition can optimize the response characteristics of biosensors by designing suitable parameters, such as the amounts of active ingredients and the thickness of the films [61,62,63,64].
A quartz slide was coated with an LbL-deposited s-β-CD/PAH film to develop fluorescence sensors for lithocholic acid (LA) [65]. The 10-bilayer (s-b-CD/PAH)10 film was doped with the organic dye neutral red (NR) by host–guest complexation. The fluorescence of NR was greatly increased by being included in the s-β-CD cavity in the film. In contrast, the fluorescence intensity decreased in response to LA as a result of competitive binding of LA to s-β-CD, which expelled NR from the s-β-CD cavity. The (s-b-CD/PAH)10 film-coated sensor could detect LA in the concentration range of 1–60 mM.
Au electrodes were coated with LbL films consisting of β-CD-capped Au nanoparticles (β-CD-AuNP) and iron(Ⅲ) tetra-(N-methyl-4-pyridyl)porphyrin (FeTMPyP) to construct electrochemical sensors for dissolved O2 [66,67]. FeTMPyP catalyzed the reduction of dissolved O2 in the range of 0.2–6.5 mg·L–1. Notably, the catalytic activity of the β-CD-AuNP/FeTMPyP film remained unchanged during 200 successive measurements of 6.5 mg·L–1 O2 in buffer solution, demonstrating the high stability of the film. This sensor may be useful as an alternative to Clark O2 sensors. Anticancer drug-loaded silica particles coated with LbL films composed of CD-bearing hyaluronic acid and porphyrin derivative have also been reported [68]. The LbL film-coated silica particles were useful for fluorescence imaging and photodynamic cancer therapy.
Electronic nose systems comprising LbL films of β-CD were developed by using LbL film-coated interdigitated electrodes [69,70]. Chemically modified b-CDs and their polymers were combined with reduced graphene oxide or carbon nanotubes to produce conductive LbL films on the electrodes. The changes in the electric resistance of the LbL films were measured as a function of various volatile organic compounds (VOCs) including methanol, ethanol, propanol, isopropanol, formaldehyde, acetone, benzene, toluene, and p-xylene. The sensors prepared from amino-and diamino-modified b-CDs exhibited a high selectivity for polar protic compounds, whereas benzyl-substituted b-CD-based sensors were selective for non-polar VOCs. A potential use of the electronic nose systems for diagnosis of lung cancers was suggested because some VOCs are biomarkers of lung cancer. Analyzing VOC profiles in exhaled breath with pattern recognition algorithms may allow diagnosis of lung cancer.
Protein-based biosensors are currently widespread as analytical tools in biomedical laboratories and hospitals. Negatively charged s-β-CD and myoglobin (Mb) were used to construct electrochemical biosensors for O2 and H2O2 [71]. s-β-CD/Mb LbL films were prepared on the surface of electrodes through electrostatic affinity. The s-b-CD/Mb film-modified electrodes exhibited electrocatalytic activity for the reduction of O2 and H2O2 owing to the heme Fe(Ⅲ)/Fe(Ⅱ) redox couple in Mb. In other works, horseradish peroxidase (HRP) was immobilized on an electrode surface to construct enzyme biosensors for H2O2, in which Ad-modified HRP (Ad-HRP) and β-CD-bearing carboxymethylcellulose (β-CD-CMC) were used to construct LbL layers [72] (Figure 6). The biosensor exhibited a linear response to H2O2 in the concentration range of 1.0 × 10–4–3.9 × 10–3 M with a detection limit of 2.0 × 10–6 M. The H2O2 sensors were stable, retaining 96% activity of their original response after 30 days storage in a phosphate buffer at pH = 7.0. β-CD-bearing PAMAM dendrimer was also used instead of β-CD-CMC to construct H2O2 sensors [73].
Figure 6. An LbL film composed of Ad-HRP and β-CD-CMC. Reprinted with permission from Villalonga et al. [72].Antibacterial surfaces are crucial in the development of biomedical devices, such as biosensors, drug delivery systems, and artificial organs. A variety of protocols for preparing antibacterial coatings have been studied, including LbL deposition [74]. Recently, CD-containing LbL films have been used for preparing antibacterial coatings, in which b-CD modified with quaternary ammonium residues was incorporated in polyamine LbL films [75,76]. The CD-containing films killed more than 95% of the attached pathogenic bacteria (Figure 7). The dead bacteria could be removed from the surface by immersing the film in surfactant solution and the antibacterial surface was regenerable. It was also reported that LbL films composed of β-CD-bearing PEI and Fc-modified chitosan suppressed bacterial adhesion [77].
Figure 7. Preparation of regenerable antibacterial LbL film composed of PAH, Ad-bearing PAA and quaternary ammonium-modified CD. Reprinted with permission from Chen et al. [75].Hollow microcapsules can be prepared by LbL deposition on the surface of microparticles followed by dissolution of the core particles (Figure 1b). It is noted here that CD-containing microcapsules are satisfactorily stable during the core dissolution probably due to the multi-point binding between CD-and guest-modified polymers. These microcapsules can accommodate drugs in the cavity or the shell. LbL film-based microcapsules can be prepared from a broad range of shell materials. Thus, CD-containing microcapsules are valuable as drug carriers because CDs can form host–guest complexes.
Several groups reported the preparation of LbL film-based microcapsules through host–guest complexation. LbL microcapsules prepared with Fc-[78] and Ad-modified polymers [79,80] exhibited pH-dependent permeability to model drugs, whereas the microcapsule shell made of azobenzene polymers [81,82] was photosensitive. The diameters of these microcapsules are typically 5–10 μm, which depends on the size of core particles used. Consequently, these microcapsules may be suitable for controlled drug release triggered by pH changes and photoirradiation, because the nanostructures of the films can be altered by the external stimuli. In the extreme case, LbL microcapsules may decompose upon exposure to the stimuli, resulting in a burst release of encapsulated drugs.
Biodegradable microcapsules containing anticancer drug paclitaxel (PTX) were prepared through electrostatic affinity between β-CD-bearing hyaluronic acid and poly(L-lysine) [83] (Figure 8). Notably, the microcapsules bind specifically to breast cancer cells (MDA-MB-231) through the hyaluronic acid receptor overexpressed on the cancer cells, decreasing the viability of cancer cells due to the increased local concentration of PTX.
Figure 8. PTX-containing microcapsule that binds to breast cancer cells (left) and the release profile of PTX from the capsule in phosphate buffer (right). Reprinted with permission from Auzely-Velty et al. [83].Hydrophobic drugs with poor solubility can be solubilized in water through forming host–guest complexes with CDs [84,85,86]. Thus, encapsulating hydrophobic drugs into LbL microcapsules may be a promising way to control the release of hydrophobic drugs. β-CD complexes of coumarin and Nile red were encapsulated as model drugs into LbL microcapsules [87]. To construct the coumarin-and Nile red-containing microcapsules, β-CD complexes of coumarin or Nile red were loaded on CaCO3 microparticles, and then the microparticles were coated with poly(styrene sulfonate) and PAH layers. Hollow microcapsules were obtained by dissolving the CaCO3 core, leaving β-CD complexes of coumarin or Nile red in the cavity. The release rate of the model drugs from the microcapsules depended on the pH of the medium.
LbL films deposited on the surfaces of flat substrates and microspheres are also useful as drug carriers for controlled release. Various types of LbL films have been combined with CDs to exploit their host–guest complexation. For instance, polyanionic β-CD synthesized by crosslinking b-CD with citric acid was deposited on the surface of a polyethylene terephthalate textile to form LbL coatings [88,89]. The LbL coatings can take up 4-tert-butylbenzoic acid (TBBA), as a model drug, through β-CD complexation. The release of TBBA from the LbL coatings depended on the number of layers in the film. In another study, poly(acrylonitrile) membranes were used as substrates for LbL film coatings [90,91]. LbL films were prepared by using cationic and anionic β-CD polymers synthesized by epichlorohydrin crosslinking. The antibacterial and antifungal drug triclosan was loaded on the LbL film through complexation with the β-CD polymers and the release profile was studied.
Biodegradable nanoparticles, such as poly(lactic acid/glycolic acid) and poly(lactic acid) (PLA) nanoparticles, are versatile carriers for drug delivery systems [92,93]. PLA nanoparticles were coated with LbL films consisting of cationic and anionic β-CD polymers [94]. The lipophilic model drug benzophenone (BP) was loaded on the LbL coatings through host–guest complexation to control the release rate. The release rate of BP was controlled based on the partition equilibrium between free BP and BP included in the β-CD cavity. These examples demonstrate the potential use of CD-containing LbL films and microcapsules for the controlled release of drugs, especially of poorly soluble hydrophobic drugs. Recently, self-healing properties of CD-containing LbL films have been reported by Ge and coworkers [95,96]. These LbL films may be useful for future applications in the development of controlled release systems.
CD-containing LbL films and microcapsules have been synthesized by using electrostatic affinity or host–guest complexation as driving forces. In the former route, charged CDs are used as film components in combination with oppositely charged polymers. In contrast, CD polymers and guest molecule-modified polymers are used in the latter route. In most cases, CDs can still bind to guest compounds to form inclusion complexes in LbL assemblies. Biosensors and controlled release systems have been developed by exploiting the binding ability of CDs in the films and microcapsules. CD-containing LbL film-coated electrodes are useful for constructing electrochemical biosensors that detect small molecules such as VOCs, O2, and H2O2. In addition, CD-containing LbL assemblies are useful as drug carriers for controlled release. Hydrophobic, poorly soluble drugs can be loaded on CD-containing LbL films and microcapsules to develop controlled delivery systems. A major advantage of LbL films is that the amount of CD can be controlled precisely by changing the number of layers in the film, which enables the performance characteristics of CD-containing LbL assemblies to be regulated. β-CD is the most widely used CD in LbL assemblies, but the use of α-and γ-CDs would also be promising because these CDs exhibit binding selectivity different from that of β-CD. Furthermore, modified CDs that contain substituents, such as methyl, acetyl, and hydroxypropyl groups, may be useful for the future development of CD-containing LbL assemblies.
The authors declare no conflict of interest.
| [1] |
Sudhof TC (2004) The synaptic vesicle cycle. Annu Rev Neurosci 27: 509-547. doi: 10.1146/annurev.neuro.26.041002.131412
|
| [2] |
Schweizer FE, Ryan TA (2006) The synaptic vesicle: cycle of exocytosis and endocytosis. Curr Opin Neurobiol 16: 298-304. doi: 10.1016/j.conb.2006.05.006
|
| [3] |
Dittman J, Ryan TA (2009) Molecular circuitry of endocytosis at nerve terminals. Annu Rev Cell Dev Biol 25: 133-160. doi: 10.1146/annurev.cellbio.042308.113302
|
| [4] |
Kuromi H, Kidokoro Y (1998) Two distinct pools of synaptic vesicles in single presynaptic boutons in a temperature-sensitive Drosophila mutant, shibire. Neuron 20: 917-925. doi: 10.1016/S0896-6273(00)80473-0
|
| [5] |
Richards DA, Guatimosim C, Betz WJ (2000) Two endocytic recycling routes selectively fill two vesicle pools in frog motor nerve terminals. Neuron 27: 551-559. doi: 10.1016/S0896-6273(00)00065-9
|
| [6] |
Mohrmann R, de Wit H, Connell E, et al. (2013) Synaptotagmin interaction with SNAP-25 governs vesicle docking, priming, and fusion triggering. J Neurosci 33: 14417-14430. doi: 10.1523/JNEUROSCI.1236-13.2013
|
| [7] |
Verstreken P, Ly CV, Venken KJT, et al. (2005) Synaptic Mitochondria Are Critical for Mobilization of Reserve Pool Vesicles at Drosophila Neuromuscular Junctions. Neuron 47: 365-378. doi: 10.1016/j.neuron.2005.06.018
|
| [8] |
Pelassa I, Zhao C, Pasche M, et al. (2014) Synaptic vesicles are . Front Mol Neurosci 7: 91-. doi: 10.3389/fnmol.2014.00091
|
| [9] | Benmerah A, Bayrou M, Cerf-Bensussan N, et al. (1999) Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci 112 (Pt 9): 1303-1311. |
| [10] |
Watanabe S, Trimbuch T, Camacho-Perez M, et al. (2014) Clathrin regenerates synaptic vesicles from endosomes. Nature 515: 228-233. doi: 10.1038/nature13846
|
| [11] |
Shimizu H, Kawamura S, Ozaki K (2003) An essential role of Rab5 in uniformity of synaptic vesicle size. J Cell Sci 116: 3583-3590. doi: 10.1242/jcs.00676
|
| [12] |
Satoh AK, O'Tousa JE, Ozaki K, et al. (2005) Rab11 mediates post-Golgi trafficking of rhodopsin to the photosensitive apical membrane of Drosophila photoreceptors. Development 132: 1487-1497. doi: 10.1242/dev.01704
|
| [13] |
Stenmark H (2009) Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10: 513-525. doi: 10.1038/nrm2728
|
| [14] |
Polymeropoulos MH, Lavedan C, Leroy E, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. doi: 10.1126/science.276.5321.2045
|
| [15] |
Kruger R, Kuhn W, Muller T, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108. doi: 10.1038/ng0298-106
|
| [16] |
Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett 345: 27-32. doi: 10.1016/0014-5793(94)00395-5
|
| [17] |
Iwai A, Masliah E, Yoshimoto M, et al. (1995) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475. doi: 10.1016/0896-6273(95)90302-X
|
| [18] |
Singleton AB, Farrer M, Johnson J, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841. doi: 10.1126/science.1090278
|
| [19] |
Jao CC, Der-Sarkissian A, Chen J, et al. (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A 101: 8331-8336. doi: 10.1073/pnas.0400553101
|
| [20] |
Abd-Elhadi S, Honig A, Simhi-Haham D, et al. (2015) Total and Proteinase K-Resistant alpha-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease. Sci Rep 5: 11120. doi: 10.1038/srep11120
|
| [21] |
Cooper AA, Gitler AD, Cashikar A, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328. doi: 10.1126/science.1129462
|
| [22] |
Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398. doi: 10.1038/35006074
|
| [23] |
Periquet M, Fulga T, Myllykangas L, et al. (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27: 3338-3346. doi: 10.1523/JNEUROSCI.0285-07.2007
|
| [24] |
Chu Y, Morfini GA, Langhamer LB, et al. (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135: 2058-2073. doi: 10.1093/brain/aws133
|
| [25] |
Bayer TA, Jakala P, Hartmann T, et al. (1999) Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10: 2799-2803. doi: 10.1097/00001756-199909090-00019
|
| [26] |
Abeliovich A, Schmitz Y, Farinas I, et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252. doi: 10.1016/S0896-6273(00)80886-7
|
| [27] | Cabin DE, Shimazu K, Murphy D, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807. |
| [28] |
Busch DJ, Oliphint PA, Walsh RB, et al. (2014) Acute increase of alpha-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. Mol Biol Cell 25: 3926-3941. doi: 10.1091/mbc.E14-02-0708
|
| [29] |
Wang L, Das U, Scott DA, et al. (2014) alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 24: 2319-2326. doi: 10.1016/j.cub.2014.08.027
|
| [30] |
Breda C, Nugent ML, Estranero JG, et al. (2015) Rab11 modulates alpha-synuclein-mediated defects in synaptic transmission and behaviour. Hum Mol Genet 24: 1077-1091. doi: 10.1093/hmg/ddu521
|
| [31] |
Paisan-Ruiz C, Jain S, Evans EW, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600. doi: 10.1016/j.neuron.2004.10.023
|
| [32] |
Zimprich A, Biskup S, Leitner P, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607. doi: 10.1016/j.neuron.2004.11.005
|
| [33] |
Nuytemans K, Theuns J, Cruts M, et al. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31: 763-780. doi: 10.1002/humu.21277
|
| [34] |
Simon-Sanchez J, Schulte C, Bras JM, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312. doi: 10.1038/ng.487
|
| [35] |
Satake W, Nakabayashi Y, Mizuta I, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307. doi: 10.1038/ng.485
|
| [36] |
Yao C, Johnson WM, Gao Y, et al. (2013) Kinase inhibitors arrest neurodegeneration in cell and C elegans models of LRRK2 toxicity. Hum Mol Genet 22: 328-344. doi: 10.1093/hmg/dds431
|
| [37] | West AB, Moore DJ, Choi C, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232. |
| [38] |
Smith WW, Pei Z, Jiang H, et al. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102: 18676-18681. doi: 10.1073/pnas.0508052102
|
| [39] |
Tong Y, Pisani A, Martella G, et al. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 106: 14622-14627. doi: 10.1073/pnas.0906334106
|
| [40] |
Imai Y, Gehrke S, Wang HQ, et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27: 2432-2443. doi: 10.1038/emboj.2008.163
|
| [41] |
Imai Y, Kobayashi Y, Inoshita T, et al. (2015) The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway. PLoS Genet 11: e1005503. doi: 10.1371/journal.pgen.1005503
|
| [42] |
Rivero-Rios P, Gomez-Suaga P, Fernandez B, et al. (2015) Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease. Biochem Soc Trans 43: 390-395. doi: 10.1042/BST20140301
|
| [43] |
Lee S, Liu HP, Lin WY, et al. (2010) LRRK2 Kinase Regulates Synaptic Morphology through Distinct Substrates at the Presynaptic and Postsynaptic Compartments of the Drosophila Neuromuscular Junction. J Neurosci 30: 16959-16969. doi: 10.1523/JNEUROSCI.1807-10.2010
|
| [44] |
Matta S, Van Kolen K, da Cunha R, et al. (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75: 1008-1021. doi: 10.1016/j.neuron.2012.08.022
|
| [45] |
Arranz AM, Delbroek L, Van Kolen K, et al. (2015) LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. J Cell Sci 128: 541-552. doi: 10.1242/jcs.158196
|
| [46] |
Piccoli G, Condliffe SB, Bauer M, et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31: 2225-2237. doi: 10.1523/JNEUROSCI.3730-10.2011
|
| [47] |
Yun HJ, Park J, Ho DH, et al. (2013) LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med 45: e36. doi: 10.1038/emm.2013.68
|
| [48] |
Shin N, Jeong H, Kwon J, et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314: 2055-2065. doi: 10.1016/j.yexcr.2008.02.015
|
| [49] |
Yun HJ, Kim H, Ga I, et al. (2015) An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem 157: 485-495. doi: 10.1093/jb/mvv005
|
| [50] |
Kessels MM, Qualmann B (2002) Syndapins integrate N-WASP in receptor-mediated endocytosis. EMBO J 21: 6083-6094. doi: 10.1093/emboj/cdf604
|
| [51] |
Kim Y, Kim S, Lee S, et al. (2005) Interaction of SPIN90 with dynamin I and its participation in synaptic vesicle endocytosis. J Neurosci 25: 9515-9523. doi: 10.1523/JNEUROSCI.1643-05.2005
|
| [52] |
Soulet F, Yarar D, Leonard M, et al. (2005) SNX9 regulates dynamin assembly and is required for efficient clathrin-mediated endocytosis. Mol Biol Cell 16: 2058-2067. doi: 10.1091/mbc.E04-11-1016
|
| [53] |
Dodson MW, Zhang T, Jiang C, et al. (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21: 1350-1363. doi: 10.1093/hmg/ddr573
|
| [54] |
Dodson MW, Leung LK, Lone M, et al. (2014) Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo. Dis Model Mech 7: 1351-1363. doi: 10.1242/dmm.017020
|
| [55] |
Esteves AR, M GF, Santos D, et al. (2015) The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm. Mol Neurobiol 52: 1804-1820. doi: 10.1007/s12035-014-8980-6
|
| [56] |
Gomez-Suaga P, Rivero-Rios P, Fdez E, et al. (2014) LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet 23: 6779-6796. doi: 10.1093/hmg/ddu395
|
| [57] |
Tong Y, Yamaguchi H, Giaime E, et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884. doi: 10.1073/pnas.1004676107
|
| [58] |
Alegre-Abarrategui J, Christian H, Lufino MM, et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-4034. doi: 10.1093/hmg/ddp346
|
| [59] |
Tong Y, Giaime E, Yamaguchi H, et al. (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7: 2. doi: 10.1186/1750-1326-7-2
|
| [60] |
Vilarino-Guell C, Wider C, Ross OA, et al. (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89: 162-167. doi: 10.1016/j.ajhg.2011.06.001
|
| [61] |
Zimprich A, Benet-Pages A, Struhal W, et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89: 168-175. doi: 10.1016/j.ajhg.2011.06.008
|
| [62] |
Nothwehr SF, Bruinsma P, Strawn LA (1999) Distinct domains within Vps35p mediate the retrieval of two different cargo proteins from the yeast prevacuolar/endosomal compartment. Mol Biol Cell 10: 875-890. doi: 10.1091/mbc.10.4.875
|
| [63] |
Korolchuk VI, Schutz MM, Gomez-Llorente C, et al. (2007) Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci 120: 4367-4376. doi: 10.1242/jcs.012336
|
| [64] |
Kumar KR, Weissbach A, Heldmann M, et al. (2012) Frequency of the D620N Mutation in VPS35 in Parkinson Disease. Arch Neurol 69: 1360-1364. doi: 10.1001/archneurol.2011.3367
|
| [65] |
Ando M, Funayama M, Li Y, et al. (2012) VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 27: 1413-1417. doi: 10.1002/mds.25145
|
| [66] |
Follett J, Norwood SJ, Hamilton NA, et al. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic 15: 230-244. doi: 10.1111/tra.12136
|
| [67] |
Zavodszky E, Seaman MN, Moreau K, et al. (2014) Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat Commun 5: 3828-. doi: 10.1038/ncomms4828
|
| [68] |
McGough IJ, Steinberg F, Jia D, et al. (2014) Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation. Curr Biol 24: 1670-1676. doi: 10.1016/j.cub.2014.06.024
|
| [69] |
Temkin P, Lauffer B, Jager S, et al. (2011) SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors. Nat Cell Biol 13: 715-721. doi: 10.1038/ncb2252
|
| [70] |
Zech T, Calaminus SD, Caswell P, et al. (2011) The Arp2/3 activator WASH regulates alpha5beta1-integrin-mediated invasive migration. J Cell Sci 124: 3753-3759. doi: 10.1242/jcs.080986
|
| [71] |
Vilarino-Guell C, Rajput A, Milnerwood AJ, et al. (2014) DNAJC13 mutations in Parkinson disease. Hum Mol Genet 23: 1794-1801. doi: 10.1093/hmg/ddt570
|
| [72] |
Popoff V, Mardones GA, Bai SK, et al. (2009) Analysis of Articulation Between Clathrin and Retromer in Retrograde Sorting on Early Endosomes. Traffic 10: 1868-1880. doi: 10.1111/j.1600-0854.2009.00993.x
|
| [73] |
Freeman CL, Hesketh G, Seaman MNJ (2014) RME-8 coordinates the activity of the WASH complex with the function of the retromer SNX dimer to control endosomal tubulation. J Cell Sci 127: 2053-2070. doi: 10.1242/jcs.144659
|
| [74] |
Munsie LN, Milnerwood AJ, Seibler P, et al. (2015) Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. Hum Mol Genet 24: 1691-1703. doi: 10.1093/hmg/ddu582
|
| [75] |
Wang HS, Toh J, Ho P, et al. (2014) In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Mol Brain 7: 73. doi: 10.1186/s13041-014-0073-y
|
| [76] |
Wen L, Tang FL, Hong Y, et al. (2011) VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J Cell Biol 195: 765-779. doi: 10.1083/jcb.201105109
|
| [77] |
MacLeod DA, Rhinn H, Kuwahara T, et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77: 425-439. doi: 10.1016/j.neuron.2012.11.033
|
| [78] |
Beilina A, Rudenko IN, Kaganovich A, et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 111: 2626-2631. doi: 10.1073/pnas.1318306111
|
| [79] |
Linhart R, Wong SA, Cao J, et al. (2014) Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2). Mol Neurodegener 9: 23. doi: 10.1186/1750-1326-9-23
|
| [80] |
Edvardson S, Cinnamon Y, Ta-Shma A, et al. (2012) A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 7: e36458. doi: 10.1371/journal.pone.0036458
|
| [81] |
Koroglu C, Baysal L, Cetinkaya M, et al. (2013) DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 19: 320-324. doi: 10.1016/j.parkreldis.2012.11.006
|
| [82] |
Fotin A, Cheng YF, Sliz P, et al. (2004) Molecular model for a complete clathrin lattice from electron cryomicroscopy. Nature 432: 573-579. doi: 10.1038/nature03079
|
| [83] |
Young JC, Barral JM, Hartl FU (2003) More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci 28: 541-547. doi: 10.1016/j.tibs.2003.08.009
|
| [84] |
Pankratz N, Wilk JB, Latourelle JC, et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593-605. doi: 10.1007/s00439-008-0582-9
|
| [85] |
Yim YI, Sun T, Wu LG, et al. (2010) Endocytosis and clathrin-uncoating defects at synapses of auxilin knockout mice. Proc Natl Acad Sci U S A 107: 4412-4417. doi: 10.1073/pnas.1000738107
|
| [86] |
Dumitriu A, Pacheco CD, Wilk JB, et al. (2011) Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet 20: 1478-1487. doi: 10.1093/hmg/ddr026
|
| [87] |
Krebs CE, Karkheiran S, Powell JC, et al. (2013) The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat 34: 1200-1207. doi: 10.1002/humu.22372
|
| [88] |
Nalls MA, Pankratz N, Lill CM, et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46: 989-993. doi: 10.1038/ng.3043
|
| [89] | Luo WJ, Chang A (1997) Novel genes involved in endosomal traffic in yeast revealed by suppression of a targeting-defective plasma membrane ATPase mutant. Mol Biol Cell 8: 1779-1779. |
| [90] |
Verstreken P, Koh TW, Schulze KL, et al. (2003) Synaptojanin is recruited by Endophilin to promote synaptic vesicle uncoating. Neuron 40: 733-748. doi: 10.1016/S0896-6273(03)00644-5
|
| [91] |
Harris TW, Hartwieg E, Horvitz HR, et al. (2000) Mutations in synaptojanin disrupt synaptic vesicle recycling. J Cell Biol 150: 589-599. doi: 10.1083/jcb.150.3.589
|
| [92] |
Schuske KR, Richmond JE, Matthies DS, et al. (2003) Endophilin is required for synaptic vesicle endocytosis by localizing synaptojanin. Neuron 40: 749-762. doi: 10.1016/S0896-6273(03)00667-6
|
| [93] |
Periquet M, Corti O, Jacquier S, et al. (2005) Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 95: 1259-1276. doi: 10.1111/j.1471-4159.2005.03442.x
|
| [94] |
Kitada T, Pisani A, Porter DR, et al. (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104: 11441-11446. doi: 10.1073/pnas.0702717104
|
| [95] |
Morais VA, Verstreken P, Roethig A, et al. (2009) Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med 1: 99-111. doi: 10.1002/emmm.200900006
|
| [96] |
Vincent A, Briggs L, Chatwin GF, et al. (2012) parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum Mol Genet 21: 1760-1769. doi: 10.1093/hmg/ddr609
|
| [97] |
Shiba-Fukushima K, Inoshita T, Hattori N, et al. (2014) PINK1-Mediated Phosphorylation of Parkin Boosts Parkin Activity in Drosophila. PLoS Genet 10: e1004391. doi: 10.1371/journal.pgen.1004391
|
| [98] |
Braschi E, Goyon V, Zunino R, et al. (2010) Vps35 Mediates Vesicle Transport between the Mitochondria and Peroxisomes. Curr Biol 20: 1310-1315. doi: 10.1016/j.cub.2010.05.066
|
| [99] |
Tang FL, Liu W, Hu JX, et al. (2015) VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. Cell Rep 12: 1631-1643. doi: 10.1016/j.celrep.2015.08.001
|
| [100] |
Cali T, Ottolini D, Negro A, et al. (2012) alpha-Synuclein Controls Mitochondrial Calcium Homeostasis by Enhancing Endoplasmic Reticulum-Mitochondria Interactions. J Biol Chem 287: 17914-17929. doi: 10.1074/jbc.M111.302794
|
| [101] |
Nakamura K, Nemani VM, Azarbal F, et al. (2011) Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein alpha-Synuclein. J Biol Chem 286: 20710-20726. doi: 10.1074/jbc.M110.213538
|
| [102] |
Wong YC, Holzbaur EL (2014) Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc Natl Acad Sci U S A 42: E4439-48. doi: 10.1073/pnas.1405752111
|
| [103] |
Guardia-Laguarta C, Area-Gomez E, Rub C, et al. (2014) alpha-Synuclein Is Localized to Mitochondria-Associated ER Membranes. J Neurosci 34: 249-259. doi: 10.1523/JNEUROSCI.2507-13.2014
|
| 1. | Uichi Akiba, Daichi Minaki, Jun-ichi Anzai, Photosensitive Layer-by-Layer Assemblies Containing Azobenzene Groups: Synthesis and Biomedical Applications, 2017, 9, 2073-4360, 553, 10.3390/polym9110553 | |
| 2. | Cen Lin, Erwin R. Stedronsky, Luke R. Jordan, Nathan J. Wittenberg, Steven L. Regen, A plug and socket approach for tightening polyelectrolyte multilayers, 2018, 54, 1359-7345, 9769, 10.1039/C8CC04550J | |
| 3. | Uichi Akiba, Daichi Minaki, Jun-ichi Anzai, Host-Guest Chemistry in Layer-by-Layer Assemblies Containing Calix[n]arenes and Cucurbit[n]urils: A Review, 2018, 10, 2073-4360, 130, 10.3390/polym10020130 | |
| 4. | Mariana A. Fernández, O. Fernando Silva, Raquel V. Vico, Rita H. de Rossi, Complex systems that incorporate cyclodextrins to get materials for some specific applications, 2019, 480, 00086215, 12, 10.1016/j.carres.2019.05.006 | |
| 5. | Luminiţa Fritea, Mihaela Tertiş, Cecilia Cristea, Robert Săndulescu, Exploring the Research Progress about the Applications of Cyclodextrins and Nanomaterials in Electroanalysis, 2023, 35, 1040-0397, 10.1002/elan.202200014 | |
| 6. | Elena Simona Băcăiță, Cătălina Anișoara Peptu, Corina-Lenuta Savin (Logigan), Marian Luțcanu, Maricel Agop, Manifest/Non-Manifest Drug Release Patterns from Polysaccharide Based Hydrogels—Case Study on Cyclodextrin—κ Carrageenan Crosslinked Hydrogels, 2021, 13, 2073-4360, 4147, 10.3390/polym13234147 | |
| 7. | Naruthai Hongsa, Tapanee Thinbanmai, Urarika Luesakul, Kanokwan Sansanaphongpricha, Nongnuj Muangsin, A novel modified chitosan/collagen coated-gold nanoparticles for 5-fluorouracil delivery: Synthesis, characterization, in vitro drug release studies, anti-inflammatory activity and in vitro cytotoxicity assay, 2022, 277, 01448617, 118858, 10.1016/j.carbpol.2021.118858 |
Figures(3) / Tables(1)
Tsuyoshi Inoshita, Yuzuru Imai. Regulation of vesicular trafficking by Parkinson's disease-associated genes[J]. AIMS Molecular Science, 2015, 2(4): 461-475. doi: 10.3934/molsci.2015.4.461
DownLoad: 